Serum amyloid P component (APCS) iRNA compositions and methods of use thereof
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsKevin Fitzgerald, Gregory Hinkle
Life of this patent
Estimating the term…
Abstract
The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the serum amyloid P component (APCS) gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of an APCS gene and to treat subjects having an APCS-associated disease, e.g., amyloidosis, Alzheimer's disease or coronary atherosclerotic heart disease.
Claims40
A double stranded ribonucleic acid (RNAi) agent for inhibiting expression of a serum amyloid P component (APCS) gene, comprising a sense strand and an antisense strand forming a double stranded region, wherein said antisense strand comprises the nucleotide sequence 5′-UAAGUUUACAUGAUCAGUAACAG-3′ (SEO ID NO:103).
A double stranded ribonucleic acid (RNAi) agent for inhibiting expression of a serum amyloid P component (APCS) gene, comprising a sense strand and an antisense strand forming a double stranded region, wherein said antisense strand comprises the nucleotide sequence 5′-UAUACAGAUAGGAAAUUCAAAGA-3′ (SEQ ID NO:171).
Dependencies are inferred from the claim text.